Elder Pharma to invest Rs 130 cr in research facility

14 Jun 2011 Evaluate

With the domestic market looking to be phenomenal over the next two-three years, the company is investing about Rs 130 crores in its research facility, over the same period. Last year, the research facility was upgraded to focus on developing new drug delivery systems. In the second year, the team has been increased and will work on developing products to be marketed by the company and its in-licensing partners.

The company has about 25 licensing partners, whose products Elder Pharma sells in India. The company is undertaking collaborative research work in some of these partnerships. Elder Pharma's area of focus includes prescription products in women's health, nutraceuticals and pain management. At present, wound care and pain management contribute about 16 per cent to Elder's turnover and is anticipated to grow at over 15 per cent every year. Elder's products include its Rs 200-crore Shelcal, now set to be taken to Sri Lanka and Bangladesh, among other markets.

Last year, saw Elder Pharma hike its stake in UK's Neutra Health Plc to 100 per cent, besides holding 92 per cent equity in Elder Biomeda of Bulgaria. Both operations will contribute about 25 per cent of the turnover this year. The focus will be on Bulgaria, which will later be used as an access market into Europe. The plan is also to support Neutra products through different pricing, adding that they would at a later stage look at bringing some of their products into India, as well. The company looks to clock consolidated revenues of about Rs 1,300 crores, this fiscal

Peers
Company Name CMP
Sun Pharma Inds. 1719.60
Dr. Reddys Lab 1271.50
Cipla 1512.05
Zydus Lifesciences 914.90
Lupin 2108.90
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×